Navigation Links
New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
Date:10/15/2007

the study was 69 percent for Lamictal XR and 62 percent for placebo. The most common adverse events in this study were headache (Lamictal XR, 17 percent vs. placebo, 15 percent) and dizziness (Lamictal XR, 18 percent vs. placebo, 5 percent). Non-serious rash was reported as an adverse event in two patients receiving Lamictal XR and in one patient receiving placebo. One of the two patients taking Lamictal XR withdrew prematurely from the study due to non- serious rash. No serious rashes were observed in either treatment group.

About Epilepsy

Epilepsy is defined by recurrent unprovoked seizures, or changes in sensation, awareness, or behavior brought about by electrical disturbances in the brain. The kind of seizure a person has depends on which part and how much of the brain is affected by the electrical disturbance that produces seizures. Generalized seizures are seizures that involve the entire brain from the outset. Partial seizures, which are the most common form of epilepsy, involve a restricted area of the brain. In approximately 70 percent of cases, the cause of epilepsy is unknown. According to the Epilepsy Foundation, more than 3 million Americans of all ages are living with epilepsy.

About Lamictal

Lamictal XR is an investigational therapy currently under review by the Food and Drug Administration. The immediate-release formulation of Lamictal is indicated 1) as adjunctive therapy for partial seizures, primary generalized tonic-clonic seizures, and the generalized seizures of Lennox-Gastaut syndrome in adults and pediatric patients as young as 2 years and 2) for conversion to monotherapy in adults with partial seizures taking carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED.

Safety and effectiveness of Lamictal have not been established 1) as initial monotherapy, 2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate, 3) for simul
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014 /CNW/ - On Aug. 20, at ... the Canadian Medical Association (CMA) voted on and approved ... material, including medicinal cannabis. Bedrocan Cannabis Corp., a leading ... the CMA motion. The CMA is quite ... associated with smoking any plant material, including medicinal cannabis. ...
(Date:8/22/2014)... CHICAGO , Aug. 22, 2014   Zacks Equity Research ... the Bull of the Day and Panera (Nasdaq: PNRA - ... Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD ... ) and Shire (Nasdaq: SHPG - Free Report ). ... Bull of the Day : The ...
(Date:8/22/2014)... COLORADO SPRINGS, Colo. , Aug. 22, 2014 ... Company specializing in cannabis formulation-based drug development and ... of UFCM iCare,s third international medical cannabis conference ... Strasbourg, France , on October ... experts with other stakeholders, such as researchers, health ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
... 22, 2011 ResearchDx announced today the official ... CDO. Recent FDA initiatives, such ... Co-Development Concept Paper, have spurred biopharmaceutical companies, interest ... companion diagnostics. The traditional Contract Research Organization (CRO), ...
... OMER ) today announced that its exclusive license to ... been amended to include addiction and compulsive disorders in the ... Company,s discovery of a previously unknown link between PDE7 and ... it also is the first to link PDE7 to any ...
Cached Medicine Technology:ResearchDx Launches Contract Diagnostics Organization (CDO) 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 3Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 4
(Date:8/22/2014)... (EGFR) mutations found in the circulating free tumor DNA ... cancer (NSCLC) patients correlates well with the EGFR mutations ... inhibitor (TKI) therapy is approved for EGFR activating mutation ... determining mutation status is with DNA derived directly from ... A more abundant and less invasive source of tumor ...
(Date:8/22/2014)... DC (PRWEB) August 22, 2014 Paying ... little easier in the coming year for four nurse ... the National League for Nursing Foundation for Nursing ... – will share $28,000, $10,000 more than in 2013, ... Ann Kerr Endowment and Elizabeth Isaac Marcil Endowment Funds, ...
(Date:8/22/2014)... August 22, 2014 Advancements in ... some clinical applications due to their cost-effectiveness, non-invasiveness, ... innovations in ultrasound, such as the evolution of ... to keep the market moving throughout 2014 and ... can enhance not only the point-of-care (POC) testing ...
(Date:8/22/2014)... Eagerly embracing intended parents around the ... now offers the top male infertility programs — run ... fertility network of IVFinMexico.com continues to shape ... care, female and male infertility, advanced research and education. ... so eminently set by company CEO and Founder Tolga ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 CarePoint ... specialist in Internal Medicine, Geriatrics, Hospice and Palliative ... CarePoint Health Medical Group. Their system welcomes Dr. ... and experienced physicians comprise CarePoint Health Medical Group, ... in Hudson County, representing a wide range of ...
Breaking Medicine News(10 mins):Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 2Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2
... ReBuilder Medical,Technologies, Inc. (Pink Sheets: RBRM), announces ... ), "We have leased, fitted and established ... will allow us to streamline the process,of new ... facility will house,both electronic and pharmaceutical laboratories," announced ...
... &, Presidential Election May Mean for Private Equity in 2008, Jan. ... the ... credit markets in,turmoil, the economy in a seeming slowdown and a presidential ... Outlook,Conference on January 29-30 at the Grand Hyatt in New York to ...
... men with chronic anxiety are at substantially higher risk, experts ... who suffer from chronic anxiety substantially increase their risk of ... stress has been linked to an increased risk of heart ... been identified as a risk factor also. , "There is ...
... 2 diabetes are often advised to cut out sucrose (table ... has been questioned by some researchers who suggest that moderate ... the diet of patients with diabetes. Now a new study ... It showed that patients who increased their daily sugar intake ...
... tendon grafts loaded with gene therapy may soon ... that has eluded surgeons to date. According to ... Therapy, a new graft technique may provide the ... can reorganize as it heals. Such tissue-engineering approaches ...
... Haemonetics,Corporation (NYSE: HAE ) will announce its Q3FY08 earnings on January ... Conference Call Dial-In Information (888) 802-8577 ... ID: 30405896 This call will be ... dial:, (800) 642-1687 (US & Canada) ...
Cached Medicine News:Health News:ReBuilder Medical Technologies, Inc. Expands R&D of New Products 2Health News:Private Equity's Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference 2Health News:Anxiety Raises Heart Attack Risk 2Health News:Anxiety Raises Heart Attack Risk 3Health News:Carrot cake study on sugar in type 2 diabetes 2Health News:Freeze-dried tendon implants prove effective in early studies 2Health News:Freeze-dried tendon implants prove effective in early studies 3Health News:Freeze-dried tendon implants prove effective in early studies 4Health News:Freeze-dried tendon implants prove effective in early studies 5
... combination of the Aliquoting System RSD 800A ... ACM-8). This turns out in an efficient ... laboratory. The System automates all important front-end ... via cap identification, sample quality control, decapping, ...
... The Aliquoting System RSD 800A is an ... and archiving (additional tube type identification via ... to process various sample tubes in a ... sorting areas are customized and offer high ...
... Sorting System RS 800 can sort different ... manual sorting are not necessary anymore and ... in a very timesaving and economical way ... Optionally a Tube Type Identification via Cap ...
... MGB Alert Detection Reagents provide molecular labs ... based assays. By using our MGB technology, ... Nanogen is now able to provide molecular ... acid sequences of specific organisms or genetic ...
Medicine Products: